Please assess the completion status of the following clinical trial:

Trial Title: S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed solitary plasmacytoma of 1 of the following types:~  * Solitary bone plasmacytoma~ * Extraosseus solitary plasmacytoma~* Bone marrow plasmacytosis \< 10% within the past 4 weeks~* Low serum and/or urine M-protein meeting ≥ 1 of the following criteria:~  * Serum IgG \< 3.5 g/dL~ * Serum IgA \< 2.0 g/dL~ * Urine M-protein (kappa or lambda) \< 1.0 g/24 hours~* No lytic lesions on skeletal survey other than a single lesion associated with solitary plasmacytoma within the past 4 weeks~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Hemoglobin ≥ 10 g/dL\* AND/OR~* No hemoglobin 2 g/dL \< lower limit of normal\* (LLN) NOTE: \*Patients with a history of hemoglobin \< 10 g/dL AND/OR \< 2 g/dL \< LLN that has corrected or improved after epoetin alfa but requires continued treatment with epoetin alfa are not eligible~Hepatic~* Not specified~Renal~* Calcium ≤ 10.5 mg/dL OR~* Calcium normal~* Creatinine ≤ 2 mg/dL~Other~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or stage I or II cancer that is currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No prior high-dose steroids except to relieve neurological compromise~Radiotherapy~* Prior localized radiotherapy for myeloma allowed~* Concurrent radiotherapy allowed~Surgery~* Prior surgery for myeloma allowed~Other~* No other prior therapy for myeloma~* Concurrent enrollment in protocol SWOG-S0309 (Myeloma Specimen Repository) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- MRI and PET (Type: OTHER): Magnetic resonance imaging and positron emission tomography

Based on this trial design, predict the completion outcome and termination type (if applicable).